This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.
I’m back from my ASCO-Chicago detour. I missed you all!
This week, let’s argue over Geron’s future and consider Candel Therapeutics to illustrate why survival claims from non-randomized studies are too often red flags. I sound like a biotech nerd. I guess I am.
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) For the first time in April, biosimilars
For a pharmaceutical company that has just navigated a complicated market access journey preceded by ten-plus years of drug development, it’s a big moment when
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes
